NASDAQ:SNTI Senti Biosciences Q2 2025 Earnings Report $0.99 +0.00 (+0.07%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.99 +0.00 (+0.32%) As of 05/8/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Senti Biosciences EPS ResultsActual EPS-$0.56Consensus EPS -$0.58Beat/MissBeat by +$0.02One Year Ago EPSN/ASenti Biosciences Revenue ResultsActual Revenue$0.50 millionExpected Revenue$1.30 millionBeat/MissMissed by -$800.00 thousandYoY Revenue GrowthN/ASenti Biosciences Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Senti Biosciences Earnings HeadlinesSenti Biosciences (SNTI) Expected to Announce Earnings on TuesdayMay 3, 2026 | americanbankingnews.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.May 9 at 1:00 AM | American Alternative (Ad)Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSee More Senti Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email. Email Address About Senti BiosciencesSenti Biosciences (NASDAQ:SNTI) (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders. Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities. Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.View Senti Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/04 - 05/08Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusWater Infrastructure: Why This Boring Sector Could Get ExcitingAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely Wrong Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
